Asset evaluation in the biopharma space is highly analog and extremely complex, requiring a myriad of experts and stakeholders at the table before a decision is made. Can AI help make this process faster and less burdensome?
Find out in our latest webinar: https://vibebio.com/resources/events/how-ai-analysis-supports-drug-dev/
